The American Society of Clinical Oncology (ASCO) named Illinois Medical Oncology Society (IMOS) Board of Directors Member Blase Polite, MD, MPP, as an Advocacy Champion during the society’s 2017 Advocacy Summit on Capitol Hill in September. Advocacy Champions are ASCO volunteers who have been exceptionally active in ASCO’s advocacy activities throughout the year. Advocates meet with federal lawmakers and agencies, send personalized letters to members of Congress through ASCO’s ACT Network, engage with state lawmakers on policy priorities at the state-level, and hold site visits during congressional recesses.
“ASCO applauds this year’s Advocacy Champions for their work in educating Congress on the realities and challenges of providing cancer care,” said ASCO Government Relations Committee Chair Robin Zon, MD, FASCO, FACP. “With the continued efforts of these dedicated volunteers, we will continue to push for policies that ensure high-quality, high-value cancer care for the more than 1.6 million Americans diagnosed with cancer each year.”
October 6, 2017
Astellas Pharma US, Inc. is pleased to announce new XTANDI data from the TERRAIN trial. The XTANDI Prescribing Information has been updated to reflect results from the TERRAIN trial, a phase 2, randomized, double-blind trial vs bicalutamide in metastatic castration-resistant prostate cancer. Please see the documents below for more information.
November 14, 2016
During the IMOS Spring Conference on May 13, 2016, three fellows gave presentations and were presented with the IMOS Fellows Awards.
From left to right, Natalie Galania, MD, Fellow, University of Chicago; Pamela B. Allen, MD, Fellow, Northwestern University; Donna Krueger, RN, OCN, IMOS Secretary/Treasurer; Chadi Nabhan, MD, FACP, President–Elect, IMOS; Pankaj Kumar, MD, President, IMOS; and Hanh Mai, MD, Fellow, Loyola University Medical Center.
May 17, 2016
As many of you know, in early March, CMS proposed a program that would have a detrimental impact on our ability to provide high quality cancer care to our patients. The Medicare Part B Drug Payment Model proposes a sweeping change to Part B reimbursement, and may be implemented as early as this fall.
The state society recently sent a letter on behalf of members to our elected officials to oppose CMS’ ill-conceived proposal.
April 28, 2016
IMOS is pleased to announce the 2016 Fellows Call for Abstracts. The winning abstracts will be selected by the IMOS Board of Directors with the winning authors presenting a synopsis at the IMOS Spring Conference on May 13, 2016.
Abstracts must be submitted on or before April 22, 2016. Abstracts are accepted on a wide range of oncology topics including but not limited to: Medical Oncology, Surgical Oncology, Radiation Oncology, Patient & Survivor Issues, Clinical Trials/Interventions, Pilot Studies, Retrospective Chart Review, Palliative Care, Developmental Therapeutics, etc. This is an exciting opportunity for fellows to participate in the Society, plus all fellows receive complimentary membership with IMOS!
The Call for Abstracts is now open, click here for details on abstract submission.
Good Luck! We hope to see you on May 13th.
April 4, 2016
Last week, IMOS joined with the Association of Community Cancer Centers (ACCC), American Society of Clinical Oncology (ASCO), the Community Oncology Alliance (COA), and approximately 100 other organizations in a letter to HHS Secretary Sylvia Burwell and Acting CMS Administrator Andy Slavitt expressing “strong concern” about the agency’s plans to put forward a proposed rule for the Medicare Part B Drug Payment Model and asking the agency not to proceed with the initiative.
The rule is scheduled to be published in the March 11 Federal Register. Comments on the proposed rule are due by May 9.
March 9, 2016
The U.S. Food and Drug Administration (FDA) on Sept. 22, 2015, approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other treatments.
October 8, 2015
To raise awareness and advance cancer treatment and science, the American Cancer Society and Genentech have teamed up to provide About Clinical Trials (ACT).
ACT is a series of unbiased videos and patient resources. Study participants, clinicians, thought leaders, nurses, and others share their experience in order to educate and inspire patients, caregivers, and physicians to act by considering enrollment in cancer clinical trials. Society Chief Medical Officer Otis W. Brawley, MD, is featured.
Go to LearnAboutClincialTrials.org to learn more about clinical trials and access resources to help patients make educated decisions about their treatment, including the American Cancer Society's Clinical Trials Matching Service. Constituents may also call the American Cancer Society National Call Information Center (NCIC) at 800.227.2345 to receive a free patient kit, which contains an educational brochure with a DVD and USB drive, and also directs inquiries to the Clinical Trials Matching Service.
August 25, 2015
August 27 at Noon, EST, join Niesha Griffith, RPh, MS, FASHP, Administrator of Oncology Pharmacy and Infusion Services at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University and Bill McGivney, PhD, Principal of McGivney Global Advisers for a complimentary webinar to discuss the intricate coverage and reimbursement issues related to immuno-oncology agents. Brought to you by the Institute for Clinical Immuno-Oncology (ICLIO) An Institute of ACCC.
Discussion will include:
-Determination of coverage and reimbursement for I-O agents
-Present coverage for I-O agents
-Impact of new Oncology Value Metrics
-Institutional considerations and needs
-Assurance of explicit, timely, and clear coverage policies
-Reimbursement issues in contracting, pilot projects etc.
Click here to register.
August 14, 2015
Four oncology fellows were honored at the annual IMOS Fellows Research Competition on August 20, 2015, at the Willis Tower in Chicago.
From left: Hanh Mai, MD; Robert Daly, MD; Randy Sweis, MD; Board Member: Chadi Nabhan, MD, FACP; and Stephanie Tsai, MD
Bobby Daly, MD
University of Chicago Medical Center
Characterizing Terminal Oncology ICU Hospitalizations
Hanh Mai, MD
Loyola University Medical Center
Comparison of 21-gene Recurrence Score (RS) with the 70-Gene Signature (GS) as a continuous variable, Magee equations, and Adjuvant! Online (AOL)
Randy Sweis, MD
University of Chicago Medical Center
Targetable molecular drivers of immunotherapy resistance in urothelial bladder cancer
Stephanie Tsai, MD
University of Chicago Medical Center
Frequency and Risk Factors Associated with Cord Graft Failure (CGF) after Allogeneic Stem Cell Transplantation with Single Unit Umbilical Cord Cells Supplemented by Haploidentical Cells (Haplo-Cord) with Reduced-Intensity Conditioning
August 11, 2015
ACCC members are invited to join Dr. Michael Postow for an interactive webinar on the role of immunotherapy in treating patients with advanced melanoma. As part of the Principles and Application of Immunotherapy of Cancer series, this free, CME/ANCC/APCE-certified webinar will be held this Friday, May 22, from 7:30 am - 8:30 am ET.
Your cancer program can host a private webinar on integrating immunotherapy into the treatment of melanoma or lung cancer, at no charge. Email Lorna Lucas or call 866.690.9902 for more information.
May 20, 2015
The Association of Community Cancer Centers (ACCC), on behalf of IMOS, has joined HHS' Health Care Payment Learning and Action Network, a collaborative network of payers, employers, providers, patients, states, and consumer groups, who will work together to generate knowledge, capture best practices, disseminate information, and apply lessons learned that support the increased adoption of value-based payments in Medicare.
The network was created in tandem with HHS Secretary Burwell's January announcement that set tangible goals to shift Medicare payments towards value-based payments.
April 3, 2015
On Feb. 18, 2015, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma.
Read company press release here.
March 3, 2015